Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.

about

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.

Item

http://www.wikidata.org/entity/Q36884436

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cisplatin/Tegafur/Uracil/Irino ...... : A Phase I/II Clinical Study.

@en

type

Item

label

Cisplatin/Tegafur/Uracil/Irino ...... : A Phase I/II Clinical Study.

@en

prefLabel

Cisplatin/Tegafur/Uracil/Irino ...... : A Phase I/II Clinical Study.

@en

P1476

Cisplatin/Tegafur/Uracil/Irino ...... : A Phase I/II Clinical Study.

@en

P2093

Muh-Hwa Yang

http://www.w3.org/2001/XMLSchema#string

Peter Mu-Hsin Chang

http://www.w3.org/2001/XMLSchema#string

San-Chi Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck.

Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.

P304

537-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2015-0515

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27091418

http://www.w3.org/2001/XMLSchema#string

P932

4861372

http://www.w3.org/2001/XMLSchema#string